Longevity PapersAbout
← All papers
RESEARCH PAPER / 2026-10-31

Inhibition of asparagine endopeptidase extends the lifespan and improves health span during aging.

Menghan Yang, Xin Meng, Zhongyun Xie, Mengmeng Wang, Zhengjiang Qian, Keqiang Ye

Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China. · pubmed

Abstract

Asparagine endopeptidase (AEP), also known as legumain, is a lysosomal cysteine protease whose activity increases with age and contributes to age-related tissue dysfunction. We tested whether chronic AEP inhibition could slow aging phenotypes in naturally aged mice. Here, we show that chronic treatment with the AEP inhibitor #11a extended lifespan and improved health span in aged C57BL/6 mice, together with reduced frailty and improved physical and cognitive performance. #11a treatment also attenuated several senescence- and inflammation-associated readouts in multiple organs. Mechanistically, #11a treatment suppressed AEP-dependent cleavage of nicotinamide phosphoribosyltransferase (NAMPT), accompanied by an increased NAD

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Chronic inhibition of asparagine endopeptidase (AEP) extends lifespan and improves health span in aged mice by preserving NAD+ levels. This is relevant because it identifies a specific enzymatic mechanism (AEP-mediated NAMPT cleavage) that drives age-related metabolic decline, offering a potential therapeutic target to slow the aging process rather than just treating symptoms.

Author of this paper? Send a correction.